AR050365A1 - Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. - Google Patents
Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.Info
- Publication number
- AR050365A1 AR050365A1 ARP050103202A ARP050103202A AR050365A1 AR 050365 A1 AR050365 A1 AR 050365A1 AR P050103202 A ARP050103202 A AR P050103202A AR P050103202 A ARP050103202 A AR P050103202A AR 050365 A1 AR050365 A1 AR 050365A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- optionally substituted
- independent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Los compuestos representados por la formula (1) o los estereoisomeros o sales farmacéuticamente aceptables de los mismos, son inhibidores de por lo menos dos quinasas de Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3beta, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, y KDR en animales, incluyendo seres humanos, para el tratamiento y/o prevencion de varias enfermedades y trastornos tales como cáncer. Reivindicacion 1: La presente se refiere a compuestos de la formula (1) o a una sal farmacéuticamente aceptyable de los mismos, en la cual X es N o C-CN; Cy es como se muestra en los restos de formulas (2); Z es hetarilo, -alquiloC1-6-O-alquiloC1-6-, -alquiloC0-6-(heterociclilo), -alquiloC0*- 6-(hetarilo), -C(O)-alquiloC0-6, -C(O)-alquiloC0-6-O-alquiloC0-6, -C(O)-alquiloC0-6-O-alquiloC1-6-O-alquiloC0-6, -C(O)-alquiloC0-6-N(alquiloC0-6)(alquiloC0-6), -C(O)-alquiloC0-6-(heterociclilo), -C(O)-alquiloC0-6-(heterociclilo)-C(O)-alquiloC0-6, - C(O)-alquiloC0-6-(hetarilo), -S(O)2-alquiloC0-6, -S(O)2-N(alquiloC0-6)(alquiloC0-6), o -S(O)2-(hetarilo), donde cualquiera de alquilo, heterociclilo, o hetarilo está opcionalmente sustituido con 1-6, halo, OH, -alquiloC0-6-O-alquiloC0-6, -alquiloC0- 6-N(alquiloC0-6)(alquiloC0-6), -C(O)-alquiloC0-6-N(alquiloC0-6)(alquiloC0-6), -C(O)-alquiloC0-6-(heterociclilo), o -alquiloC0-6 independientes o como se muestra en el grupo de formulas (3) o Z es como se muestra en los restos de formulas (4) en las cuales el enlace ondulado es el punto de union, y donde las porciones piperazina o morfolina están opcionalmente sustituidas con 1-6 grupos alquilo C0-6 independientes; Y es -C(alquiloC0-6)(alquiloC0-6)-, -N(alquiloC0-6)-, -N(alquiloC0-6)-alquiloC1- 6-, O, S, >N-alquiloC2-6-N-(alquiloC0-6)(alquiloC0-6), >N-lquiloC2-6-O-alquiloC0-6, >N-alquiloC1-6-C(O)-NH-alquiloC0-6, o >N-alquiloC2-6-N-C(O)-alquiloC1-6; y R1 es arilo, hetarilo, o heterociclilo, opcionalmente sustituido con 1-6 sustituyentes independientes de halo, -CN, -OH,-alquiloC0-6, cicloalquiloC3-10, -haloalquiloC1-6, -alquiniloC2-6, -N(alquiloC0-6)(alquiloC0-6), -C(O)-alquiloC0-6-N(alquiloC0-6)(alquiloC0-6), -C(O)-alquiloC0-6-(heterociclilo), -alquiloC1-6-C(O)-alquiloC0-6- N(alquiloC0-6)(alquiloC0-6), -O-alquiloC0-6-(heterociclilo), -alquiloC0-6-O-alquiloC0-6, -alquiloC0-6-N(alquiloC0-6)(alquiloC0-6), -O-alquiloC0-6-(hetarilo), -S(O)2-N(alquiloC0-6)(alquiloC0-6), arilo, hetarilo o heterociclilo, o sustituidos con un oxo (=O) usando un enlace del anillo arilo, hetarilo o heterociclilo, donde cualquiera de los sustituyentes está opcionalmente sustituido con 1-6 independientes de halo, CN, OH, -alquiloC0-6-O-alquiloC0-6, -alquiloC0-6-N(alquiloC0-6)(alquiloC0-6), - C(O)-alquiloC0-6-N(alquiloC0-6)(alquiloC0-6), -C(O)-alquiloC0-6-(heterociclilo), o alquiloC0-6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59817304P | 2004-08-02 | 2004-08-02 | |
US69851605P | 2005-07-12 | 2005-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050365A1 true AR050365A1 (es) | 2006-10-18 |
Family
ID=35839836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103202A AR050365A1 (es) | 2004-08-02 | 2005-08-01 | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US7465726B2 (es) |
EP (1) | EP1797054A2 (es) |
JP (1) | JP2008508358A (es) |
AR (1) | AR050365A1 (es) |
BR (1) | BRPI0514094A (es) |
CA (1) | CA2575808A1 (es) |
MX (1) | MX2007001399A (es) |
TW (1) | TW200615268A (es) |
WO (1) | WO2006017443A2 (es) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE423120T1 (de) * | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
HUP0400891A2 (en) * | 2004-04-29 | 2006-04-28 | Janos Szolcsanyi | 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds |
ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
KR20080023680A (ko) | 2005-05-10 | 2008-03-14 | 인터뮨, 인크. | 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체 |
RU2435769C2 (ru) | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
EP1919905B1 (en) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
AU2006284900A1 (en) * | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
JP2009507792A (ja) | 2005-08-29 | 2009-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20070129364A1 (en) * | 2005-12-07 | 2007-06-07 | Han-Qing Dong | Pyrrolopyridine kinase inhibiting compounds |
PL1962830T3 (pl) * | 2005-12-23 | 2013-08-30 | Glaxosmithkline Llc | Azaindolowe inhibitory kinaz aurora |
CA2651732C (en) | 2006-05-18 | 2014-10-14 | Mannkind Corporation | Intracellular kinase inhibitors |
WO2008005538A2 (en) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
ATE526327T1 (de) * | 2006-07-06 | 2011-10-15 | Abbott Healthcare Products Bv | Azaindolderivate mit einer kombination eines teilweisen agonismus am nikotinischen acetylcholinrezeptor und einer inhibierung der dopaminwiederaufnahme |
US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
CA2697147A1 (en) | 2007-07-26 | 2009-02-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
ES2424977T3 (es) * | 2007-08-08 | 2013-10-10 | Glaxosmithkline Intellectual Property Development Limited | Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer |
WO2009030088A1 (fr) * | 2007-09-05 | 2009-03-12 | Second Military Medical University | Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline |
AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
WO2009063240A1 (en) * | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
EP2628727A3 (en) * | 2007-11-21 | 2013-12-25 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders |
EP2229368A1 (en) | 2007-12-11 | 2010-09-22 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
EP2252601B1 (en) | 2008-01-24 | 2012-12-19 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8598160B2 (en) | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
CN102089300B (zh) | 2008-05-01 | 2014-06-18 | 生命医药公司 | 11β-羟基类固醇脱氢酶1的环状抑制剂 |
WO2009134387A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
CN102105454A (zh) | 2008-07-25 | 2011-06-22 | 贝林格尔.英格海姆国际有限公司 | 合成1型11β-羟基类固醇脱氢酶的抑制剂 |
US8846668B2 (en) | 2008-07-25 | 2014-09-30 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
RU2539979C2 (ru) | 2008-07-25 | 2015-01-27 | Вайтаи Фармасьютиклз, Инк. | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 |
ES2467109T3 (es) | 2008-08-20 | 2014-06-11 | Zoetis Llc | Compuestos de pirrolo[2,3-d]pirimidina |
WO2010045451A1 (en) * | 2008-10-16 | 2010-04-22 | Glaxosmithkline Llc | Pyrrolopyrimidine compounds |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
US8637505B2 (en) | 2009-02-04 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8680093B2 (en) | 2009-04-30 | 2014-03-25 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8927539B2 (en) | 2009-06-11 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure |
US9951008B2 (en) * | 2009-11-03 | 2018-04-24 | University Of Notre Dame Du Lac | Ionic liquids comprising heteraromatic anions |
JP5750449B2 (ja) | 2009-11-05 | 2015-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規キラルリンリガンド |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
FR2953839A1 (fr) * | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
FR2953836B1 (fr) * | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
WO2011111880A1 (ko) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
WO2011112666A1 (en) | 2010-03-09 | 2011-09-15 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
RU2594742C2 (ru) | 2010-05-20 | 2016-08-20 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
US8648192B2 (en) | 2010-05-26 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
JP5860042B2 (ja) | 2010-06-16 | 2016-02-16 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 置換5、6及び7員複素環、そのような化合物を含有する医薬及びそれらの使用 |
WO2011161128A1 (en) | 2010-06-25 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
AU2011325286B2 (en) | 2010-11-02 | 2015-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
JP2014510265A (ja) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Igf−1rの阻害に関する方法および組成物 |
ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
CA2852127C (en) | 2011-11-11 | 2020-10-27 | Duke University | Combination drug therapy for the treatment of solid tumors |
EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
WO2013174735A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Substituted benzothienopyrimidines |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
WO2014048869A1 (en) | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
CA2885787A1 (en) | 2012-09-26 | 2014-04-03 | Lars Wortmann | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
JP6298472B2 (ja) | 2012-11-19 | 2018-03-20 | ノバルティス アーゲー | 寄生虫病の処置のための化合物および組成物 |
JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系cdk9キナーゼ阻害薬 |
EP2970268A1 (en) | 2013-03-13 | 2016-01-20 | AbbVie Inc. | Cdk9 kinase inhibitors |
CA2903538A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
WO2014151444A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
CA2905530A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
WO2015048765A1 (en) | 2013-09-30 | 2015-04-02 | University Of Notre Dame Du Lac | Compounds, complexes, compositions, methods and systems for heating and cooling |
US10086331B2 (en) | 2013-11-05 | 2018-10-02 | University Of Notre Dame Du Lac | Carbon dioxide capture using phase change ionic liquids |
EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
JP6038111B2 (ja) * | 2014-12-27 | 2016-12-07 | ヤマサ醤油株式会社 | 多置換7−デアザプリン誘導体合成のための2,6−ジクロロ−8−ヨード−7−デアザプリン |
MX2018000577A (es) | 2015-07-16 | 2018-09-05 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa. |
MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
PT3269370T (pt) | 2016-02-23 | 2020-03-05 | Taiho Pharmaceutical Co Ltd | Novo composto de pirimidina condensada ou sal do mesmo |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
US20200165203A1 (en) * | 2017-07-31 | 2020-05-28 | Washington University | Use of pirfenidone and derivatives for modulation of b lymphocyte activity and organ protection from acute tissue damage |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
CN111285882B (zh) * | 2018-12-07 | 2022-12-02 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
CN113874015A (zh) | 2018-12-21 | 2021-12-31 | 细胞基因公司 | Ripk2的噻吩并吡啶抑制剂 |
EP4048656A4 (en) * | 2019-10-22 | 2023-11-29 | Alphala Co., Ltd. | PYRROLAMIDE COMPOUNDS AND USE THEREOF |
US11814388B1 (en) | 2020-08-28 | 2023-11-14 | Ferris State University | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers |
CN113583007B (zh) * | 2021-08-31 | 2022-06-10 | 山东大学 | 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用 |
GB202215117D0 (en) * | 2022-10-13 | 2022-11-30 | Norwegian Univ Sci & Tech Ntnu | Compound |
GB202215132D0 (en) * | 2022-10-13 | 2022-11-30 | Norwegian Univ Sci & Tech Ntnu | Compound |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958930A (en) * | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
US5877178A (en) * | 1991-04-08 | 1999-03-02 | Duquesne University Of The Holy Ghost | Pyrimidine derivatives and methods of making and using these derivatives |
CZ1598A3 (cs) * | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
EP0888349B1 (en) * | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
US6537999B2 (en) * | 1996-06-06 | 2003-03-25 | Duquesne University Of The Holy Ghost | Pyrimidine derivatives and methods of making and using these derivatives |
DK0938486T3 (da) * | 1996-08-23 | 2008-07-07 | Novartis Ag | Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
ATE264318T1 (de) * | 1996-11-19 | 2004-04-15 | Amgen Inc | Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel |
WO1998043973A1 (de) | 1997-03-27 | 1998-10-08 | Novartis Ag | Zwischenprodukte und verfahren zur herstellung von pyrimidinderivaten |
US6187778B1 (en) * | 1997-08-05 | 2001-02-13 | Pfizer Inc. | 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists |
HUP0100348A3 (en) * | 1997-10-20 | 2002-12-28 | Hoffmann La Roche | Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
HUP0102574A3 (en) | 1998-06-19 | 2002-01-28 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US6664252B2 (en) * | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
ITMI992711A1 (it) * | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
AU1312502A (en) * | 2000-10-11 | 2002-04-22 | Pe Corp Ny | Fluorescent nucleobase conjugates having anionic linkers |
AU2002223684A1 (en) * | 2000-11-22 | 2002-06-03 | Novartis Pharma Gmbh | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
AP2003002929A0 (en) | 2001-06-23 | 2003-12-31 | Aventis Pharma Inc | Pyrrolopyrimidines as protein kinase inhibitors |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
FR2842525B1 (fr) * | 2002-07-16 | 2005-05-13 | Aventis Pharma Sa | Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant |
TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2004013141A1 (en) * | 2002-08-06 | 2004-02-12 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
US20040138238A1 (en) * | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
-
2005
- 2005-08-01 BR BRPI0514094-3A patent/BRPI0514094A/pt not_active IP Right Cessation
- 2005-08-01 US US11/194,158 patent/US7465726B2/en not_active Expired - Fee Related
- 2005-08-01 JP JP2007524889A patent/JP2008508358A/ja active Pending
- 2005-08-01 TW TW094126065A patent/TW200615268A/zh unknown
- 2005-08-01 WO PCT/US2005/027274 patent/WO2006017443A2/en active Search and Examination
- 2005-08-01 AR ARP050103202A patent/AR050365A1/es not_active Application Discontinuation
- 2005-08-01 CA CA002575808A patent/CA2575808A1/en not_active Abandoned
- 2005-08-01 EP EP05778352A patent/EP1797054A2/en not_active Withdrawn
- 2005-08-01 MX MX2007001399A patent/MX2007001399A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2006017443A2 (en) | 2006-02-16 |
JP2008508358A (ja) | 2008-03-21 |
EP1797054A2 (en) | 2007-06-20 |
BRPI0514094A (pt) | 2008-05-27 |
US20060211678A1 (en) | 2006-09-21 |
WO2006017443A3 (en) | 2007-01-18 |
US7465726B2 (en) | 2008-12-16 |
MX2007001399A (es) | 2007-04-18 |
TW200615268A (en) | 2006-05-16 |
CA2575808A1 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050365A1 (es) | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. | |
AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
UY28873A1 (es) | Nuevos compuestos de morfina composiciones y procedimientos de preparación | |
PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
UY30641A1 (es) | Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
PE20091095A1 (es) | Moduladores de gamma secretasa | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
ECSP088863A (es) | Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia | |
PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
AR070487A1 (es) | Derivados de 3- metil- imidazo -( 1,2-b)- piridazina | |
AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
PE20080527A1 (es) | Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k) | |
AR049319A1 (es) | Derivados de 6-heteroarilfenantridinas | |
AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |